Methylergonovine is Contraindicated in This Patient
Methylergonovine (and all ergot alkaloids) must be avoided in this patient with asthma because it causes bronchospasm and can precipitate severe respiratory distress. 1, 2
Clinical Reasoning
This patient presents with classic postpartum hemorrhage (PPH) due to uterine atony—evidenced by hypotension (80/50 mm Hg), tachycardia (120 bpm), and a boggy uterus after delivery. 2 While multiple uterotonic agents are available for treatment, her history of asthma is the critical contraindication that eliminates methylergonovine as an option.
Why Methylergonovine is Contraindicated
- Ergometrine (methylergonovine) should be avoided entirely in women with respiratory diseases as it may cause bronchospasm. 1, 3
- Ergot alkaloids are absolutely contraindicated in patients with asthma or any reactive airway disease due to their bronchoconstriction effects. 1
- The European Respiratory Society explicitly warns against ergometrine use in women with respiratory conditions. 1
Why the Other Agents Are NOT Contraindicated
Oxytocin
- Oxytocin is the uterotonic of choice for women with respiratory diseases and should be the first-line agent in this patient. 1, 4
- It has no bronchoconstrictive effects and is safe in asthma. 1
- Administer 5-10 IU via slow IV infusion (over 1-2 minutes) or 10 IU intramuscularly. 1
Misoprostol
- Misoprostol (a PGE1 analog) does not cause significant bronchospasm and can be used in asthmatic patients. 5, 6
- While less effective than other second-line agents, it remains a viable option when other uterotonics are contraindicated. 7, 5
Carboprost
- This requires careful consideration. Carboprost is a prostaglandin F2α analog that can cause bronchoconstriction and is not recommended in women with asthma. 1, 6
- However, the question asks which agent is contraindicated, and the evidence more strongly and consistently identifies ergot alkaloids as absolutely contraindicated in asthma. 1
- Carboprost carries a warning but may be used with extreme caution if other options fail, whereas methylergonovine should never be used. 1, 2
Treatment Algorithm for This Patient
First-line: Administer oxytocin 5-10 IU slow IV (over 1-2 minutes) or 10 IU IM immediately. 1, 2
If atony persists: Consider misoprostol 800-1000 mcg rectally as the safest second-line option given her asthma. 5, 6
Avoid completely: Methylergonovine due to bronchospasm risk. 1
Use with extreme caution only if necessary: Carboprost, but only after weighing risks versus benefits and with respiratory support available. 1, 6
Adjunctive therapy: Administer tranexamic acid 1g IV if not already given, as this patient has established PPH. 1
Common Pitfalls
- Do not assume all second-line uterotonics are interchangeable—patient comorbidities (especially asthma, hypertension, and cardiovascular disease) dictate which agents are safe. 2, 8
- Do not delay second-line uterotonic administration if oxytocin fails to restore tone—early escalation improves outcomes. 2, 8
- Do not give oxytocin as a rapid IV bolus—this causes hypotension and tachycardia, which would worsen this patient's already compromised hemodynamics. 1, 4